News Archives - Ethyreal Bio

Ethyreal Bio Emerges from Stealth with $101 Million in Financing to Advance ETHY-001, a Potentially Best-in-Class Anti-TSHR Antibody for Thyroid Eye Disease and Graves’ Disease

CAMBRIDGE, Mass., June 10, 2026 – Ethyreal Bio (“Ethyreal” or “the Company”), a biotechnology company...

By Daniel Nunez|2026-06-10T07:26:31-04:00June 10, 2026|News|0 Comments

Ethyreal Bio, Inc.

700 Technology Sq, FL 3
Cambridge, MA 02139
United States

700 Technology Sq, FLR 3
Cambridge, MA 02139
United States

ETHY-001 is an investigational therapy and has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory authority. Its safety and efficacy have not been established. The information on this website is intended for educational purposes and does not constitute medical advice. Please consult your healthcare provider with any questions about your condition or treatment.